Vireo Growth (VREOF) Net Income towards Common Stockholders (2020 - 2026)
Vireo Growth (VREOF) reported Net Income towards Common Stockholders of -$22.5 million for Q1 2026, down 562.98% on a YoY basis from $4.9 million in Q1 2025, and up 33.39% sequentially from -$33.8 million in Q4 2025.
Vireo Growth (VREOF) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$22.5 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 562.98% year-over-year to -$22.5 million; the trailing twelve-month figure through Mar 2026 stood at -$49.8 million (down 384.51% YoY), and the FY2025 full-year result was -$81.5 million, down 598.32% from the prior year.
- Net Income towards Common Stockholders advanced to -$22.5 million in Q1 2026, from -$33.8 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $4.9 million in Q1 2025 to a low of -$33.8 million in Q4 2025.
- A 5-year average of -$5.3 million and a median of -$5.7 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders soared 176.72% in 2024 and sank 903.06% in 2025, its largest moves.
- Tracing VREOF's Net Income towards Common Stockholders over 5 years: stood at -$9.3 million in 2022, then jumped by 138.44% to $3.6 million in 2023, then climbed by 17.77% to $4.2 million in 2024, then slumped by 903.06% to -$33.8 million in 2025, then soared by 33.39% to -$22.5 million in 2026.
- Business Quant data shows VREOF's Net Income towards Common Stockholders at -$22.5 million in Q1 2026, -$33.8 million in Q4 2025, and $2.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -22.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.50 Mn |
| Dec 31, 2025 | -33.78 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 3.67 Mn |
| Mar 31, 2025 | 4.86 Mn |
| Dec 31, 2024 | 4.21 Mn |
| Sep 30, 2024 | 4.40 Mn |
| Jun 30, 2024 | 4.06 Mn |
| Mar 31, 2024 | 3.70 Mn |
| Dec 31, 2023 | 3.57 Mn |
| Sep 30, 2023 | -5.73 Mn |
| Jun 30, 2023 | -7.39 Mn |
| Mar 31, 2023 | -8.47 Mn |
| Dec 31, 2022 | -9.29 Mn |
| Sep 30, 2022 | -9.57 Mn |
| Jun 30, 2022 | -6.10 Mn |
| Mar 31, 2022 | -17.68 Mn |
| Dec 31, 2021 | -14.09 Mn |
| Sep 30, 2021 | -6.84 Mn |
| Jun 30, 2021 | -6.99 Mn |